Breast Cancer Clinical Trial
Official title:
Evaluation of the Predictive and Prognostic Value of Germ-line Polymorphisms in Patients With Metastatic Breast Cancer : a Multicenter Non-randomized Prospective Cohort Study
This is a multicenter, non-randomized, prospective cohort study. The purpose of the study is
to identify germ line genetic factors that influence the risk of metastatic breast cancer.
1500 patients will be enrolled in this study. Blood samples will be collected after informed
consent and inclusion in the study.
Patients will be treated and followed according to the standards of their treating center.
They will be followed during at least 5 years every 6 months for 3 years then every year.
The StoRM trial is designed for analysis in association with the SIGNAL study which aims to
decipher the genetic risk of breast cancer displaying amplification of the HER2 gene as well
as resistance or toxicity to adjuvant treatments. SIGNAL study is in the process of
recruiting 6000 localized breast cancer patients.
The purpose of the StoRM trial is to create a cohort of 1500 patients with metastatic breast
cancer including detailed epidemiologic and treatment data. Using germ line polymorphisms in
these patients and comparing them to patients with localized cancer from the SIGNAL study,
the investigators will answer questions specific to the genetic influence on the prognosis of
breast cancer and its response to treatments in the metastatic phase.
Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent
and inclusion in the study. To simplify the evolution of the study and to avoid all
confusion, the sample collection procedures followed will be identical to those used in the
SIGNAL study.
As the samples are received at the biological resource center, the plasma will be aliquoted
into a 500 µl tube and frozen at -80° C. DNA will be extracted using standard protocols.
Plasma and DNA will be stored in anticipation of genetic analyses. An aliquot of the DNA
sample will be genotyped for a panel of high-density genetic markers covering the whole
genome, for genome-wide association studies.
The collected plasma may also be used for analyses to determine the expression profile of
proteins, alone or combined with genetic factors that allow distinguishing between groups of
patients.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |